WallStSmart
BBNX

Beta Bionics, Inc. Common Stock

NASDAQ: BBNX · HEALTHCARE · MEDICAL DEVICES

$9.85
+0.00% today

Updated 2026-06-05

Market cap
$540.09M
P/E ratio
P/S ratio
4.90x
EPS (TTM)
$-1.37
Dividend yield
52W range
$9 – $33
Volume
1.0M

Beta Bionics, Inc. Common Stock (BBNX) Earnings

Quarterly earnings history, analyst estimates, and stock price reaction.

EPS beat streak
3 of 7
Last 7 quarters
Avg EPS surprise
+8.2%
Last 4 quarters
Revenue YoY growth
+56.6%
Most recent quarter
EPS YoY growth
+61.5%
Most recent quarter

Earnings surprise history (last 12 quarters)

Beat estimate Missed estimate

Quarterly EPS and revenue trend

Quarterly revenue EPS (diluted)

How the stock reacts to earnings

Avg 1-day reaction
+6.2%
Last 4 reports
Positive reaction rate
50%
2 of 4 quarters
Largest single-day move
+19.8%
2025-07-29
Report dateEPS actualSurpriseClose beforeClose after1-day reaction
2026-04-21$-0.36-8.6%$12.91$12.20-5.5%
2026-02-17$-0.30+21.1%$13.94$13.61-2.4%
2025-10-28$-0.33+13.2%$23.75$26.79+12.8%
2025-07-29$-0.39+7.1%$13.99$16.76+19.8%

Quarterly earnings history

Fiscal quarter endingEPS estimateEPS actualSurpriseRevenueYoY revenue
2026-03-31$-0.33$-0.36-8.6%$27.63M+56.6%
2025-12-31$-0.38$-0.30+21.1%$32.12M+57.1%
2025-09-30$-0.38$-0.33+13.2%$27.25M+63.1%
2025-06-30$-0.42$-0.39+7.1%$23.24M
2025-03-31$-0.42$-0.93-121.4%$17.64M
2024-12-31$-1.22$-2.72-123.6%$20.44M
2024-09-30$0.00$-0.82$16.70M

Frequently asked questions

Has Beta Bionics, Inc. Common Stock beaten earnings estimates?

Beta Bionics, Inc. Common Stock has beaten Wall Street EPS estimates in 3 of its last 7 quarterly reports, averaging a +8.2% surprise over the last 4. A consistent beat record suggests management guides conservatively and the business has predictable momentum, which tends to support the stock through earnings season.

How does BBNX stock react to earnings?

BBNX has moved an average of +6.2% the day after earnings over its last 4 reports, finishing higher after 2 of them. Next-day moves show how the market digests results in the short term, and repeated dips on strong reports usually mean expectations were already priced in.

What is Beta Bionics, Inc. Common Stock's revenue growth rate?

Beta Bionics, Inc. Common Stock reported year-over-year revenue growth of +56.6% in its most recent quarter, with EPS up +61.5%. EPS outpacing revenue is operating leverage at work, meaning profit is compounding faster than sales.